|
Back to Home » March 2018 News » eTheRNA Completes Enrolment of Low Dose Cohort for Phase 1b Study of TriMix mRNA-based Cancer Specific Immunotherapy (ECI-006) in Melanoma |
eTheRNA Completes Enrolment of Low Dose Cohort for Phase 1b Study of TriMix mRNA-based Cancer Specific Immunotherapy (ECI-006) in Melanoma |
March 19, 2018
NIEL, Belgium, March 19, 2018 /PRNewswire/ --
ECI-006 is safe and well tolerated
eTheRNA immunotherapies, a clinical-stage company developing novel cancer immunotherapies based on its unique mRNA-based TriMix platform, announces that it has completed enrolment of the low dose...
Source URL: https://www.prnewswire.com/news-releases/etherna-completes-enrolment-of-low-dose-cohort-for-phase-1b-study-of-trimix-mrna-based-cancer-specific-immunotherapy-eci-006-in-melanoma-677234353.html
|
|
|
|
